Thermo Clinical Analyzer Provides Range of Laboratory Tests
By LabMedica International staff writers Posted on 30 Jun 2017 |
Image: An operator stands at the control screen of the Cascadion clinical analyzer (Photo courtesy of Thermo Fisher Scientific).
A new mass spectrometry-based clinical analyzer has been introduced marking a potentially significant development in mass spectrometry evolution as a clinical technology. The analyzer brings together the ease of use of clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The fully automated analyzer is designed for use in a variety of settings, including hospital laboratories, and to provide results for a range of clinical tests. The analyzer is intended for analysis of small molecules, and the instrument will allow clinical laboratories to run mass spec-based assays without employing staff specially trained on mass spectrometry.
Mass spectrometry offers greater sensitivity and specificity than immunoassays, and for molecules like Vitamin D and certain hormones where antibody-based tests can have trouble distinguishing between closely related forms, it could enable more accurate testing. Given this potential advantage, scientists and clinicians have explored use of this technology for years for these sorts of assays.
The Cascadion SM clinical analyzer (Thermo Fisher Scientific, Waltham, MA, USA) is designed as a turnkey solution to enable clinical laboratories to easily adopt the power and capabilities of LC-MS/MS as the gold standard in screening and diagnostic testing. The Cascadion system combines assays, software, accessories, consumables and support/service in a standalone system designed to meet the regulatory requirements for routine and specialized clinical testing. Designed as a fully automated sample-in and result-out workflow, development features include: gold standard mass spectrometry technology, complete assay kits for standardized results, and traceability of results to reagent lots.
Alan Sachs, MD, PhD, chief scientific officer at Thermo Fisher Scientific, said, “Thermo Fisher is uniquely positioned to deliver an automated clinical analyzer that builds on our leading mass spectrometry platform. It is designed to provide clinical laboratories with a solution that is both efficient and effective in providing results for some of the most sought after clinical tests. Cascadion has the potential to set new standards in the detection and measurement of specialty small molecule assays in the clinical laboratory.”
The Cascadion clinical analyzer was demonstrated during EuroMedLab 2017, held June 11-15, 2017 in Athens, Greece. The Cascadion will be commercially available in Europe, followed by the USA once regulatory approvals have been received.
The fully automated analyzer is designed for use in a variety of settings, including hospital laboratories, and to provide results for a range of clinical tests. The analyzer is intended for analysis of small molecules, and the instrument will allow clinical laboratories to run mass spec-based assays without employing staff specially trained on mass spectrometry.
Mass spectrometry offers greater sensitivity and specificity than immunoassays, and for molecules like Vitamin D and certain hormones where antibody-based tests can have trouble distinguishing between closely related forms, it could enable more accurate testing. Given this potential advantage, scientists and clinicians have explored use of this technology for years for these sorts of assays.
The Cascadion SM clinical analyzer (Thermo Fisher Scientific, Waltham, MA, USA) is designed as a turnkey solution to enable clinical laboratories to easily adopt the power and capabilities of LC-MS/MS as the gold standard in screening and diagnostic testing. The Cascadion system combines assays, software, accessories, consumables and support/service in a standalone system designed to meet the regulatory requirements for routine and specialized clinical testing. Designed as a fully automated sample-in and result-out workflow, development features include: gold standard mass spectrometry technology, complete assay kits for standardized results, and traceability of results to reagent lots.
Alan Sachs, MD, PhD, chief scientific officer at Thermo Fisher Scientific, said, “Thermo Fisher is uniquely positioned to deliver an automated clinical analyzer that builds on our leading mass spectrometry platform. It is designed to provide clinical laboratories with a solution that is both efficient and effective in providing results for some of the most sought after clinical tests. Cascadion has the potential to set new standards in the detection and measurement of specialty small molecule assays in the clinical laboratory.”
The Cascadion clinical analyzer was demonstrated during EuroMedLab 2017, held June 11-15, 2017 in Athens, Greece. The Cascadion will be commercially available in Europe, followed by the USA once regulatory approvals have been received.
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines